malignant haematological and neoplastic diseases
Conditions
Interventions
Group 1: Group (1) of the patients with oral anticancer therapy will be followed according to current practice by the responsible physician only.
Group 2: Group (2) with the same treatment will in ad
Sponsors
Hämatologisch-onkologische Praxis Altona
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria comprise a life expectancy of more than 5 months, the capability to care for themselves, read, understand and write in German language. Aside from the oral antineoplastic treatment no other cytoreductive agents are allowed.
Exclusion criteria
Exclusion criteria: Erxcluded are patients who are under psychiatric treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint will be the extent and frequency of side effects from the oral antitumor therapy according to the CTC – criteria, evaluated every four weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint will be the specific treatment adherence, the self-efficacy for coping with cancer, the subjective perception of side effects, the disease–related quality of life, satisfaction with information, and degree of coping. The analysis will be based on the EORTC –C30, EORTC Info 25 and CBI-B-D scales, evaluated every eight weeks. | — |
Countries
Germany
Contacts
Public ContactAnja Beylich
Hämatologisch-onkologische Praxis Altona
Outcome results
None listed